{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:29:03Z","timestamp":1777476543363,"version":"3.51.4"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.lungcan.2017.07.010","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T19:32:18Z","timestamp":1499974338000},"page":"75-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes"],"prefix":"10.1016","volume":"111","author":[{"given":"Brandon","family":"Lau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliet","family":"Burn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelyn","family":"McLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"McCaughan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2017.07.010_bib0005","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2017.07.010_bib0010","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.lungcan.2017.07.010_bib0015","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1556-0864(15)30366-X","article-title":"The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline","volume":"1","author":"Ellis","year":"2006","journal-title":"J. Thorac. Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2017.07.010_bib0020","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"10026","key":"10.1016\/j.lungcan.2017.07.010_bib0025","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2017.07.010_bib0030","series-title":"17th International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer","article-title":"Nintedanib plus pemetrexed\/cisplatin in patients with MPM: phase II findings from the placebo-controlled LUME-Meso trial","author":"Steele","year":"2016"},{"issue":"4","key":"10.1016\/j.lungcan.2017.07.010_bib0035","first-page":"428","article-title":"Systematic review of trimodality therapy for patients with malignant pleural mesothelioma","volume":"1","author":"Cao","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"issue":"8","key":"10.1016\/j.lungcan.2017.07.010_bib0040","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2017.07.010_bib0045","series-title":"World Health Organisation Classification of Tumours","article-title":"Pathology and genetics of tumours of the lung, pleura, thymus and heart","author":"Travis","year":"2004"},{"key":"10.1016\/j.lungcan.2017.07.010_bib0050","series-title":"Cancer Staging Manual","first-page":"271","article-title":"Pleural mesothelioma","author":"American Joint Committee on Cancer","year":"2010"},{"key":"10.1016\/j.lungcan.2017.07.010_bib0055","series-title":"TNM Classification of Malignant Tumours","author":"Union for International Cancer Control","year":"2009"},{"key":"10.1016\/j.lungcan.2017.07.010_bib0060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2017.07.010_bib0065","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdm501","article-title":"Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)","volume":"19","author":"Castagneto","year":"2008","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2017.07.010_bib0070","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO.2008.20.3943","article-title":"Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma","volume":"27","author":"Krug","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2017.07.010_bib0075","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/JTO.0b013e3181d86ea9","article-title":"Chemotherapy induced pathologic complete response in malignant pleural mesothelioma","volume":"5","author":"Bech","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2017.07.010_bib0080","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/JTO.0b013e3181c8cb16","article-title":"A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with carboplatin and pemetrexed","volume":"5","author":"Kao","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2017.07.010_bib0085","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/sj.bjc.6600210","article-title":"Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer","volume":"86","author":"Chollet","year":"2002","journal-title":"Br. J. Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217303896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217303896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T06:57:56Z","timestamp":1535612276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217303896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":17,"alternative-id":["S0169500217303896"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.07.010","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}